According to IMARC Group’s latest report, titled “Natural Killer Cells Therapeutics Market Size: Global Industry Trends, Share, Growth, Opportunity and Forecast 2021-2026”, the global natural killer cells therapeutics market exhibited strong growth during 2015-2020. Natural killer (NK) cells are large granular lymphocytes responsible for producing immunoregulatory cytokines. They are a type of white blood cells that act as a vital component of the human immune system. They contain small granules of special proteins such as proteases and perforin known as granzymes. NK cell therapeutics are developed through ex vivo pre-conditioning with cytokine or small molecular drugs and chimeric antigen receptor (CAR) NK. They aim at pathogenic antigens with cytotoxicity and reduce the risk of cytokine storms.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Request for a PDF sample of this report: https://www.imarcgroup.com/natural-killer-cells-therapeutics-market/requestsample
The global NK cells therapeutics market is primarily driven by their increasing utilization in various molecular and combination therapies for various treatments. They are used as effective therapeutic drugs in cases of cancer, liver and infectious diseases. Furthermore, the rising awareness regarding the importance of immunotherapies has increased the need for better therapeutic options and the launch of new products, which is expected to influence market growth in the future. As a result, several research activities have resulted in the development of allogeneic NK cells with maximum therapeutic effects. They also enhance the target and extend the persistence of potent immune cells, which helps create a strong and sustained anti-cancer immune-mediated attack. Looking forward, IMARC Group expects the market to grow at a CAGR of around 15% during 2021-2026.
Competitive Landscape with Key Players:
- Affimed GmbH
- Bristol-Myers Squibb Company
- Fate Therapeutics
- Fortress Biotech Inc.
- Glycostem Therapeutics
- Innate Pharma S.A.
- Kuur Therapeutics Inc
- Athenex Inc
- Nkarta Inc.
- Takeda Pharmaceutical Company Limited
- Ziopharm Oncology Inc.
Breakup by Therapeutics:
- NK Cell Therapies
- NK Cell Directed Antibodies
Breakup by Application:
- Gastrointestinal Diseases
- Immunoproliferative Disorders
Breakup by End User:
- Research Centers and Institutes
Breakup by Region:
Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://bit.ly/3eOi11p
We are updating our reports, If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.
Key highlights of the report:
- Market Performance (2015-2020)
- Market Outlook (2021-2026)
- Market Trends
- Market Drivers and Success Factors
- The Impact of COVID-19 on the Global Market
- Value Chain Analysis
- Structure of the Global Market
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800